SUBLEASESublease • February 27th, 2015 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances)
This Sublease (the “Sublease”) is made as of the 27th day of December 2010 by and between ALKERMES, INC., a Pennsylvania corporation having an address at 852 Winter Street, Waltham, Massachusetts 02451-1420 (“Sublandlord”), and CORREGIDOR THERAPEUTICS, INC., a Delaware corporation having an address at 384 Powder Mill Road, Concord, MA 01742 (“Subtenant”).
AMENDMENT ALease Agreement • February 27th, 2015 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances)
ASSET PURCHASE AND LICENSE AGREEMENT BY AND BETWEEN ALKERMES, INC. AND CORREGIDOR THERAPEUTICS, INC. DECEMBER 27, 2010Asset Purchase and License Agreement • February 27th, 2015 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • Massachusetts
CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. SUCH OMITTED PORTIONS, WHICH ARE MARKED WITH BRACKETS [ ] AND AN ASTERISK*, HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
LEASELease • February 27th, 2015 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
Lease dated as of the 6th day of December, 2000, by and between H&N Associates, LLC, a Massachusetts Limited Liability Company, as landlord (“Landlord”), and Advanced Inhalation Research, Inc., a Delaware Corporation, as tenant (“Tenant”).
RESTRICTED STOCK AGREEMENTRestricted Stock Agreement • February 27th, 2015 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances)
This Agreement is entered into as of the May 13, 2014 by and between ACORDA THERAPEUTICS, INC., a Delaware corporation (“Company”), and Andrew Hindman (“Employee”) at 1020 Vallejo Street, Apt 6, San Francisco, CA 94133.
AMENDMENT TO ASSET PURCHASE AND LICENSE AGREEMENTAsset Purchase and License Agreement • February 27th, 2015 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • Massachusetts
THIS AMENDMENT (the “Amendment”) is made and entered into as of December 9, 2011 to the Asset Purchase and License Agreement (the “Agreement”) made and entered into as of December 27, 2010 by and between Civitas Therapeutics, Inc., a Delaware corporation having its principal office at 190 Everett Avenue, Chelsea, MA 02150 (“Civitas”), and Alkermes, Inc., a Pennsylvania corporation having its principal office at 852 Winter Street, Waltham, MA 02451 (“Alkermes”) (any terms used but not defined herein shall have the meaning set forth in the Agreement).
AMENDMENT BLease Agreement • February 27th, 2015 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances)
SECOND AMENDMENT TO ASSET PURCHASE AND LICENSE AGREEMENTAsset Purchase and License Agreement • February 27th, 2015 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • Massachusetts
THIS SECOND AMENDMENT (the “Amendment”) is made and entered into as of December 19, 2014 to the Asset Purchase and License Agreement (the “Agreement”) made and entered into as of December 27, 2010, as amended as of December 9, 2011 by the first amendment (“Amendment No. 1”), by and between Civitas Therapeutics, Inc., a Delaware corporation having its principal office at 190 Everett Avenue, Chelsea, MA 02150 (“Civitas”), and Alkermes, Inc., a Pennsylvania corporation having its principal office at 852 Winter Street, Waltham, MA 02451 (“Alkermes”) (capitalized terms used but not defined herein shall have the meaning set forth in the Agreement).
